Although heparin-derived oligosaccharide (s)(HDO) have been clinically used for the
management of neurological disorders, such as stroke and Alzheimer's disease (AD), very
little information on the mechanism of their therapeutic action is known. To test the
hypothesis that HDO may pass through the blood–brain barrier (BBB) to mediate their
effects, a pharmacodynamic (PD) model was developed and the presence of HDO in the
cerebrospinal fluid (CSF) was used as a BBB accessibility index. Rats were treated with an …